Spitzer Ernest, Mercado Jorge, Islas Fabian, Rothenbühler Martina, Kurmann Reto, Zürcher Fabian, Krähenmann Peter, Llerena Nassip, Jüni Peter, Torres Pedro, Pilgrim Thomas
Department of Cardiology, Bern University Hospital, Bern, Switzerland.
Institute of Cardiology CardioSalud, Arequipa, Peru.
PLoS One. 2015 Jul 24;10(7):e0133004. doi: 10.1371/journal.pone.0133004. eCollection 2015.
The objective of the study was to evaluate the implications of different classifications of rheumatic heart disease on estimated prevalence, and to systematically assess the importance of incidental findings from echocardiographic screening among schoolchildren in Peru.
We performed a cluster randomized observational survey using portable echocardiography among schoolchildren aged 5 to 16 years from randomly selected public and private schools in Arequipa, Peru. Rheumatic heart disease was defined according to the modified World Health Organization (WHO) criteria and the World Heart Federation (WHF) criteria.
Among 1395 eligible students from 40 classes and 20 schools, 1023 (73%) participated in the present survey. The median age of the children was 11 years (interquartile range [IQR] 8-13 years) and 50% were girls. Prevalence of possible, probable and definite rheumatic heart disease according to the modified WHO criteria amounted to 19.7/1000 children and ranged from 10.2/1000 among children 5 to 8 years of age to 39.8/1000 among children 13 to 16 years of age; the prevalence of borderline/definite rheumatic heart disease according to the WHF criteria was 3.9/1000 children. 21 children (2.1%) were found to have congenital heart disease, 8 of which were referred for percutaneous or surgical intervention.
Prevalence of RHD in Peru was considerably lower compared to endemic regions in sub-Saharan Africa, southeast Asia, and Oceania; and paralleled by a comparable number of undetected congenital heart disease. Strategies to address collateral findings from echocardiographic screening are necessary in the setup of active surveillance programs for RHD.
ClinicalTrials.gov identifier: NCT02353663.
本研究的目的是评估风湿性心脏病不同分类对估计患病率的影响,并系统评估秘鲁学童超声心动图筛查中偶然发现的重要性。
我们在秘鲁阿雷基帕随机选择的公立和私立学校中,对5至16岁的学童进行了一项使用便携式超声心动图的整群随机观察性调查。风湿性心脏病根据修改后的世界卫生组织(WHO)标准和世界心脏联盟(WHF)标准进行定义。
在来自20所学校40个班级的1395名符合条件的学生中,1023名(73%)参与了本次调查。儿童的中位年龄为11岁(四分位间距[IQR]8 - 13岁),50%为女孩。根据修改后的WHO标准,可能、很可能和确诊的风湿性心脏病患病率为每1000名儿童19.7例,范围从5至8岁儿童中的每1000名10.2例到13至16岁儿童中的每1000名39.8例;根据WHF标准,临界/确诊的风湿性心脏病患病率为每1000名儿童3.9例。发现21名儿童(2.1%)患有先天性心脏病,其中8名被转诊进行经皮或手术干预。
与撒哈拉以南非洲、东南亚和大洋洲的流行地区相比,秘鲁风湿性心脏病的患病率相当低;未检测到的先天性心脏病数量与之相当。在建立风湿性心脏病主动监测项目时,有必要制定应对超声心动图筛查附带发现的策略。
ClinicalTrials.gov标识符:NCT02353663。